Last month, Senior Vice President of scientific affairs for the Council for Responsible Nutrition, Andrew Shao testified during a discussion with members of the Institute of Medicine of the National Academics about the benefits of biomarkers and surrogate endpoints in clinical trials for dietary supplements.
Primarily used to measure the effects of various treatments in clinical studies, surrogate endpoints or markers are the descriptions of the results or the interpreted health benefits from the evaluated study.
“The lack of validated biomarkers for exposure to nutrition interventions and as surrogate endpoints for chronic disease limits the amount of research that can be conducted, especially using prospective randomized, controlled intervention trials, due to cost and logistical issues,” Shao said.
Clinical endpoints are said to help revolutionize the way research is performed on dietary supplements, as we know it.
“We anticipate that a formal biomarker evaluation process will add clarity to product development,” Shao stated about the new findings on clinical trials for dietary supplements.
|
